Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2554 + HRS-8080 in Advanced Breast Cancer
NCT07125950Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zeprumetostat in breast cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate. Started Oct 2025; status: recruiting.
02
Drugs
zeprumetostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07125950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07125950.